An interventional study of Virtual reality-based exposure treatment with multimodal feedback (VRET-M) and Virtual reality-based exposure treatment with bimodal feedback (VRET-B) in Aerophobia, Virtual Reality Exposure Therapy and Randomized Controlled Trial, sponsored by University of Barcelona. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-11.
Sponsored by University of Barcelona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to assess whether adding vibrotactile stimulation to visual and auditory stimulation increases the efficacy of VRET for FoF treatment. Eighty-four participants (18-65 years old) will be assigned to one of three intervention arms, namely the VRET with multimodal feedback (visual, auditory, and vibrotactile; VRET-M), the VRET with bimodal feedback (visual and auditory; VRET-B), or the imagery exposure treatment (IET) without sensory feedback. FoF-related symptoms (primary outcomes) will be measured administering the Fear of Flying Questionnaire-II (QPV-II), the Fear of Flying Scale (FFS), and the Visual Analogic Scale (VAS-A) before and after eight sessions of treatment, and at six- and 12-month follow-ups. Anxiety and the sense of presence experienced during exposure sessions (secondary outcome measures: VAS-A and VAS-P) will also be assessed. It is expected that participants in the VRET-M group will report a further reduction of FoF-related symptomatology after the treatment and at follow-ups compared to participants in the VRET-B and IET groups. Likewise, participants in the VRET-M group are expected to show higher sense of presence levels during exposure sessions in comparison to participants in the VRET-B and IET groups. It is expected that the IET group will report the lowest level of sense of presence and the poorest outcome after treatment and at follow-ups.
Participants who meet the inclusion criteria will be invited to participate in the initial treatment session. They will be also required to purchase a flight ticket during the six months after the end of the treatment. Participants will be treated weekly for eight individual sessions. While the first two sessions involve preparation and training, exposure will be conducted between the third and eighth session. The exposure sessions' structure and content will be the same in all conditions. Nevertheless, the VRET-M group will experience vibrotactile cues, while the VRET-B group will not. Furthermore, the IET group will experience its own subjective imagined environment without any external stimulation.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
This study's planned enrollment of 84 is close to the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →University of Barcelona is the lead sponsor of 100 studies on the registry; 30 are open to participants now.
Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VRET with multimodal feedback including visual, auditory and vibrotactile cues.
Behavioral: Virtual reality-based exposure treatment with bimodal feedback (VRET-B) · Behavioral: Imagery exposure treatment (IET)
VRET with bimodal feedback including visual and auditory cues.
Behavioral: Virtual reality-based exposure treatment with multimodal feedback (VRET-M) · Behavioral: Imagery exposure treatment (IET)
Imagery exposure treatment without sensory cues.
Behavioral: Virtual reality-based exposure treatment with multimodal feedback (VRET-M) · Behavioral: Virtual reality-based exposure treatment with bimodal feedback (VRET-B)
The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.
The VRET-B group will experience visual and auditive cues in the exposure sessions.
The IET group will experience its own subjective imagined environment without any external stimulation.
Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).
To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.
Time frame: Before the exposure treatment.
Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).
To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.
Time frame: After eight sessions of treatment during eight weeks.
Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).
To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.
Time frame: At 6 months follow-up after treatment termination.
Fear of Flying (FoF). Administering the Fear of Flying Questionnaire-II (QPV-II) and the Fear of Flying Scale (FFS).
To what extend I feel fear about flying by plane? The QPV-II is rated from on a 10-point scale (0 = absence of anxiety, 10 = extreme anxiety) with scores ranging from 0 to 300. The FFS is rated on a 5-point scale (0 = not at all, 4 = very much), with scores ranging from 0 to 84.
Time frame: At 12 months follow-up after treatment termination.
Anxiety. Administering a Visual Analogue Scale (VAS-A).
To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).
Time frame: Before the exposure treatment.
Anxiety. Administering a Visual Analogue Scale (VAS-A).
To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).
Time frame: After eight sessions of treatment during eight weeks.
Anxiety. Administering a Visual Analogue Scale (VAS-A).
To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).
Time frame: At 6 months follow-up after treatment termination.
Anxiety. Administering a Visual Analogue Scale (VAS-A).
To what extend I feel anxious about flying by plane? measured from 0 (absence of anxiety) to 10 (extreme anxiety).
Time frame: At 12 months follow-up after treatment termination.
Anxiety. Administering a Visual Analogue Scale (VAS-A).
To what extend I feel anxious now? measured from 0 (absence of anxiety) to 10 (extreme anxiety).
Time frame: Before each exposure session.
Anxiety. Administering a Visual Analogue Scale (VAS-A).
To what extend I feel anxious now? measured from 0 (absence of anxiety) to 10 (extreme anxiety).
Time frame: Every 2 minutes during each exposure session of 60 minutes.
Anxiety. Administering a Visual Analogue Scale (VAS-A).
To what extend I feel anxious now? measured from 0 (absence of anxiety) to 10 (extreme anxiety).
Time frame: After eight sessions of treatment during eight weeks.
Sense of Presence. Administering the Visual Analogue Scale (VAS-P).
To what extend I feel present now? measured from 0 (absence of sense of presence) to 10 (extreme sense of presence).
Time frame: Every 2 minutes during each exposure session of 60 minutes.
Plan to share: No
Start is estimated for Sep 2023; primary completion for Oct 2023, 1 month later.
Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 1 month is below that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.